ACOT13 and fatty liver disease: Both pharmacological disruption of Them2–PC–TP interactions with compound A1 and genetic ablation of skeletal muscle PC-TP abrogated WT Them2-induced hepatic steatosis and insulin resistance in the setting of over nutrition.